Chlorphentermine

Chlorphentermine

Clinical data
Other names	p-Chloro-α,α-dimethylphenethylamine
Routes of administration	Oral, Insufflated, Rectal
ATC code	A08AA (WHO)
Legal status
Legal status	CA: Schedule IV UK: Class C US: Schedule III (but withdrawn from market)
Pharmacokinetic data
Elimination half-life	40 hours
Excretion	Renal
Identifiers
IUPAC name 1-(4-chlorophenyl)-2-methylpropan-2-amine
CAS Number	461-78-9 N151-06-4
PubChem CID	10007
DrugBank	DB01556 Y
ChemSpider	9613 Y
UNII	NHW07912O7
KEGG	C07559 Y
ChEMBL	ChEMBL1201269 N
CompTox Dashboard (EPA)	DTXSID0022806
ECHA InfoCard	100.006.651
Chemical and physical data
Formula	C10H14ClN
Molar mass	183.68 g·mol−1
3D model (JSmol)	Interactive image
SMILES Clc1ccc(cc1)CC(N)(C)C
InChI InChI=1S/C10H14ClN/c1-10(2,12)7-8-3-5-9(11)6-4-8/h3-6H,7,12H2,1-2H3 Y Key:ZCKAMNXUHHNZLN-UHFFFAOYSA-N Y
NY (what is this?)  (verify)

Chlorphentermine (trade names Apsedon, Desopimon, Lucofen) is a serotonergic appetite suppressant of the amphetamine family. Developed in 1962, it is the 4-chloro derivative of the better known appetite suppressant phentermine, which is still in current use.

Chlorphentermine acts as a highly selective serotonin releasing agent (SRA). It is not a psychostimulant and has little or no abuse potential, but is classed as a Schedule III drug in the USA due mainly to its similarity to other appetite suppressants such as diethylpropion which have been more widely abused. It is no longer used due mainly to safety concerns, as it has a serotonergic effects profile similar to other withdrawn appetite suppressants such as fenfluramine and aminorex which were found to cause pulmonary hypertension and cardiac fibrosis following prolonged use.

The plasma half-life is about five days. It was withdrawn from the market in the UK in 1974.

See also